Revolution Medicines, Inc. (RVMD): price, analyst ratings, earnings and fundamentals
Updated 16 September 2026, 08:02 ET
Revolution Medicines, Inc. (RVMD) closed at $204.86 on 15 September 2026, down 0.1%. The stock is up 0.6% over one month and up 340.1% over one year. It trades 8.7% below its 52-week high of $224.31. Analysts recorded 26 actions in the last 90 days; the median price target of $245 is 19.6% above the last close. The company last reported on 5 August 2026 for Q2 2026: EPS of -$3.06 against an estimate of -$2.01, a miss of 52.2%.
Price and performance
Performance figures use dividend and split adjusted closes over trading sessions, so a one-year move compares the last close with the close 252 sessions earlier. The 52-week range uses the adjusted daily highs and lows of the same window. Read the guide: Momentum, trend and technical indicators.
The live chart with technical indicators is in the app: open RVMD in FundSpec.
Analyst ratings
Over the last 90 days FundSpec recorded 26 analyst actions on RVMD from 13 firms: 25 maintained or reiterated a view and 1 initiation. Price targets were 24 raised. The most recent targets from 16 firms range from $167 to $320, with a median of $245, 19.6% above the last close.
| Date | Firm | Action | Price target |
|---|---|---|---|
| 10 Sep 2026 | Morgan Stanley | Initiates Coverage On Overweight | $255.00 |
| 9 Sep 2026 | Stifel | Maintains Buy | $215.00 to $230.00 |
| 31 Aug 2026 | Needham | Maintains Buy | $240.00 to $275.00 |
| 28 Aug 2026 | UBS | Maintains Buy | $220.00 to $265.00 |
| 28 Aug 2026 | Guggenheim | Maintains Buy | $240.00 to $275.00 |
| 27 Aug 2026 | Oppenheimer | Maintains Outperform | $230.00 to $260.00 |
| 27 Aug 2026 | RBC Capital | Maintains Outperform | $203.00 to $251.00 |
| 27 Aug 2026 | Wedbush | Maintains Outperform | $201.00 to $225.00 |
| 27 Aug 2026 | Truist Securities | Maintains Buy | $231.00 to $239.00 |
| 27 Aug 2026 | Evercore ISI Group | Maintains Outperform | $230.00 to $320.00 |
A price target is one firm's twelve-month view, and the median across firms is a steadier reading than any single call. Upgrades and downgrades matter more when they change a rating, not only a target. Read the guide: What analyst ratings and price targets actually tell you.
Every action with the firm's history is in Analyst Ratings.
Earnings
The next report is scheduled for 4 November 2026 after the close for Q3 2026, with EPS expected at -$2.41 on revenue of $19.6 million. Revolution Medicines, Inc. beat the EPS estimate in 0 of its last 8 reported quarters.
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| Q2 2026 | 5 Aug 2026 | -$2.01 | -$3.06 | -52.24% | |
| Q1 2026 | 6 May 2026 | -$1.84 | -$2.29 | -24.46% | |
| Q4 2025 | 25 Feb 2026 | -$1.56 | -$1.86 | -19.23% | |
| Q3 2025 | 5 Nov 2025 | -$1.40 | -$1.61 | -15.00% | |
| Q2 2025 | 6 Aug 2025 | -$1.05 | -$1.31 | -24.76% | |
| Q1 2025 | 7 May 2025 | -$1.05 | -$1.13 | -7.62% | |
| Q4 2024 | 26 Feb 2025 | -$0.96 | -$1.12 | -16.67% | |
| Q3 2024 | 6 Nov 2024 | $0.87 | -$0.94 | -208.05% |
An earnings surprise is the reported EPS against the consensus estimate on the day. The price reaction depends as much on guidance and on what was already priced in as on the surprise itself. Read the guide: Earnings season: estimates, surprises and price reaction.
Estimates, confirmed dates and alerts for every company are in Earnings.
Fundamentals
For the period ended 30 June 2026, Revolution Medicines, Inc. reported net income of -$644.4 million. On a trailing twelve month basis the company shows revenue growth of N.A., a gross margin of N.A., an operating margin of N.A. and a return on equity of -79.08%.
Income statement
| Line | Amount |
|---|---|
| Research and Development | $394,919,000 |
| Selling, General & Administrative Expenses | $110,213,000 |
| Depreciation & Amortization | $2,100,000 |
| Total Operating Expenses | $505,132,000 |
| Operating Profit | -$505,132,000 |
| Interest Expense | $23,781,000 |
| Pre-tax Income | -$644,371,000 |
| Net Income | -$644,371,000 |
Cash flow
| Line | Amount |
|---|---|
| Cash from Operating Activities | -$387,319,000 |
| Stock-based Compensation | $67,000,000 |
| Cash from Investing Activities | -$1,658,670,000 |
| Capital Expenditures | $2,286,000 |
| Cash from Financing Activities | $2,420,485,000 |
| Free Cash Flow | -$389,605,000 |
Assets
| Line | Amount |
|---|---|
| Cash & Cash Equivalents | $815,435,000 |
| Restricted Cash | $4,858,000 |
| Short-term Investments | $3,122,534,000 |
| Prepaid Expenses | $90,369,000 |
| Total Current Assets | $4,028,338,000 |
| Plant, Property & Equipment, Net | $34,608,000 |
| Operating Lease Right-of-Use Assets | $127,844,000 |
| Goodwill Intangible Assets, Net | $70,408,000 |
| Deferred Tax Asset | $53,883,000 |
| Other Long-term Assets | $14,760,000 |
| Total Assets | $4,323,270,000 |
Liabilities and equity
| Line | Amount |
|---|---|
| Accounts Payable & Accrued Expenses | $88,419,000 |
| Operating Lease Liabilities, Current | $16,753,000 |
| Other Current Liabilities | $5,145,000 |
| Total Current Liabilities | $354,061,000 |
| Operating Lease Liabilities, Long-term | $137,741,000 |
| Deferred Income Taxes | $2,353,000 |
| Other Liabilities | $1,648,000 |
| Total Liabilities | $1,717,032,000 |
| Common Stock | $21,000 |
| Retained Earnings | -$3,967,289,000 |
| Other Accumulated Comprehensive Income | -$5,950,000 |
| Total Stockholders Equity | $2,606,238,000 |
| Total Liability & Stockholders Equity | $4,323,270,000 |
Figures as filed with the SEC for the period ended 30 June 2026, in US dollars.
FundSpec fundamental metrics
Each metric is computed from the company's filings and ranked against every company FundSpec covers; the percentile is the share of covered companies with a lower value.
Liquidity
| Metric | Value | Percentile | What it measures |
|---|---|---|---|
| Cash Ratio | 11.12 | 96th | Calculated as the ratio of Cash and cash equivalents / Current liabilities. This metric calculates the company's ability to repay its short-term debt |
| Current Ratio | 11.38 | 95th | Calculated as the ratio of Current Assets / Current Liabilities. The higher the current ratio, the more capable the company is of paying its obligations |
Leverage
| Metric | Value | Percentile | What it measures |
|---|---|---|---|
| Debt/Assets | 0.00 | 17th | Calculated as the ratio of Short-Term Debt + Long-Term Debt / Total Assets. The higher the ratio, the higher the degree of leverage, and consequently, financial risk |
| Debt/Equity | 0.00 | 14th | Calculated as the ratio of Total Liabilities / Shareholders' Equity. The ratio indicates how much debt a company is using to finance its assets relative to the amount of value represented in shareholders’ equity |
| Degree of Financial Leverage | 0.96 | 41st | Calculated as the ratio of Percentage change in EPS / Percentage change in EBIT. A higher degree of financial leverage means that the company has more volatile EPS. |
Earnings Growth (EBIT)
| Metric | Value | Percentile | What it measures |
|---|---|---|---|
| EBIT Pct Growth | 81.3% | 57th | The EBIT growth rate over the trailing twelve months (TTM) |
| EBIT Pct Growth 3 year CAGR | -71.6% | 76th | The EBIT compound annual growth rate (CAGR) over the past 3 years |
| EBIT Pct Growth 5 year CAGR | -62.5% | 64th | The Adjusted EBIT compound annual growth rate (CAGR) over the past 5 years |
Earnings Growth (EBITDA)
| Metric | Value | Percentile | What it measures |
|---|---|---|---|
| EBITDA Pct Growth | 81.8% | 54th | The EBITDA growth rate over the trailing twelve months (TTM) |
| EBITDA Pct Growth 3 year CAGR | 400.0% | 71st | The EBITDA compound annual growth rate (CAGR) over the past 3 years |
| EBITDA Pct Growth 5 year CAGR | 400.0% | 57th | The EBITDA compound annual growth rate (CAGR) over the past 5 years |
Cashflow
| Metric | Value | Percentile | What it measures |
|---|---|---|---|
| FCF Pct Growth | 75.9% | 80th | The Free Cash Flow growth rate over the trailing twelve months (TTM) |
| FCF Pct Growth 3 year CAGR | 388.3% | 92nd | The Free Cash Flow compound annual growth rate (CAGR) over the past 3 years |
| FCF Pct Growth 5 year CAGR | 400.0% | 94th | The Free Cash Flow compound annual growth rate (CAGR) over the past 5 years |
| FCF Return on Assets Pct | -36.5% | 14th | Calculated as the ratio of Cashflow from Operations / Total Assets. A high cash return on assets means a company is generating more cash flow from every asset dollar |
| Operating Cashflow Pct Growth | 78.6% | 82nd | The Operating Cashflow growth rate over the trailing twelve months (TTM) |
| Operating Cashflow Pct Growth 3 year CAGR (FY) | -71.4% | 5th | The Operating Cashflow compound annual growth rate (CAGR) over the past 3 years |
| Operating Cashflow Pct Growth 5 year CAGR (FY) | -58.2% | 4th | The Operating Cashflow compound annual growth rate (CAGR) over the past 5 years |
Earnings Growth (Net Income)
| Metric | Value | Percentile | What it measures |
|---|---|---|---|
| Net Income Pct Growth | 117.7% | 83rd | The Net Income growth rate over the trailing twelve months (TTM) |
| Net Income Pct Growth 3 year CAGR | -81.3% | 6th | The Net Income compound annual growth rate (CAGR) over the past 3 years |
| Net Income Pct Growth 5 year CAGR | -65.4% | 5th | The Net Income compound annual growth rate (CAGR) over the past 5 years |
Profitability
| Metric | Value | Percentile | What it measures |
|---|---|---|---|
| Operating Profit Pct Growth | 81.3% | 82nd | The Operating Profit growth rate over the trailing twelve months (TTM) |
| Operating Profit Pct Growth 3 year CAGR (FY) | -71.6% | 7th | The Operating Profit compound annual growth rate (CAGR) over the past 3 years |
| Operating Profit Pct Growth 5 year CAGR (FY) | -62.5% | 5th | The Operating Profit compound annual growth rate (CAGR) over the past 5 years |
| Return on Assets Pct | -52.4% | 18th | Calculated as the ratio of Net Income / Total Assets. It is an indicator of how efficient the company is at using its assets to generate earnings. |
| Return on Equity Pct | -79.1% | 16th | Calculated as the ratio of Net Income / Shareholders' equity. It is a measure of how much profit a company generates with the money shareholders have invested. |
Margins and returns say how much of each dollar of sales becomes profit and how hard the balance sheet is working; leverage and liquidity say how much room the company has when conditions turn. Read the guide: A practical guide to discounted cash flow valuation.
Fair value, peer multiples and the full statement history are in the app: open RVMD in FundSpec.
Insider activity
In the last 90 days insiders filed 85 transactions: 21 acquisitions covering 212,416 shares and 64 disposals covering 388,734 shares. Acquisitions include awards and option exercises as well as open market purchases. The largest by value was a disposal of 35,938 shares by Mark A Goldsmith, Director, See Remarks on 21 August 2026, worth about $7.5 million at the transaction price.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 8 Sep 2026 | Lorence H. Kim | Director | Disposal | 4,730 | $210.50 | $996K |
| 8 Sep 2026 | Lorence H. Kim | Director | Disposal | 3,844 | $211.36 | $812K |
| 8 Sep 2026 | Lorence H. Kim | Director | Disposal | 3,587 | $208.55 | $748K |
| 8 Sep 2026 | Lorence H. Kim | Director | Disposal | 2,853 | $209.56 | $598K |
| 8 Sep 2026 | Lorence H. Kim | Director | Disposal | 999 | $207.33 | $207K |
| 8 Sep 2026 | Lorence H. Kim | Director | Disposal | 706 | $206.60 | $146K |
| 8 Sep 2026 | Lorence H. Kim | Director | Disposal | 371 | $212.27 | $79K |
| 31 Aug 2026 | Lorence H. Kim | Director | Disposal | 26,160 | $203.55 | $5.3M |
| 31 Aug 2026 | Lorence H. Kim | Director | Disposal | 12,919 | $202.48 | $2.6M |
| 31 Aug 2026 | Lorence H. Kim | Director | Disposal | 7,271 | $204.35 | $1.5M |
| 31 Aug 2026 | Lorence H. Kim | Director | Disposal | 6,597 | $201.47 | $1.3M |
| 31 Aug 2026 | Lorence H. Kim | Director | Disposal | 2,128 | $205.19 | $437K |
| 31 Aug 2026 | Lorence H. Kim | Director | Disposal | 625 | $206.15 | $129K |
| 31 Aug 2026 | Lorence H. Kim | Director | Disposal | 300 | $200.56 | $60K |
| 21 Aug 2026 | Mark A Goldsmith | Director, See Remarks | Disposal | 35,938 | $209.26 | $7.5M |
Insider filings record what officers and directors did with their own shares. Disposals are often planned sales or tax related, so a pattern across several insiders says more than one filing.
SEC filings
The latest filing is a 10-Q from 5 August 2026.
| Filed | Form | Document |
|---|---|---|
| 5 Aug 2026 | 10-Q | View on sec.gov |
| 6 May 2026 | 10-Q | View on sec.gov |
| 25 Feb 2026 | 10-K | View on sec.gov |
| 5 Nov 2025 | 10-Q | View on sec.gov |
| 6 Aug 2025 | 10-Q | View on sec.gov |
| 7 May 2025 | 10-Q | View on sec.gov |
| 26 Feb 2025 | 10-K | View on sec.gov |
| 6 Nov 2024 | 10-Q | View on sec.gov |
| 7 Aug 2024 | 10-Q | View on sec.gov |
| 8 May 2024 | 10-Q | View on sec.gov |
Company profile
- Exchange
- Nasdaq
- Sector
- Pharmaceuticals, Biotech and Chemicals
- Industry
- Pharmaceutical Products
- Chief executive
- Mark A. Goldsmith
- Employees
- 250
- Website
- revmed.com
- SEC CIK
- 0001628171
Revolution Medicines, Inc. focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trials for solid tumors, such as gynecologic and colorectal cancer tumors.
Sector and peers
Revolution Medicines, Inc. is part of the Pharmaceuticals, Biotech and Chemicals sector, which FundSpec tracks across 614 companies.
Companies in the same industry by market capitalization:
AMGN Amgen Inc.GILD Gilead Sciences, Inc.MRNA Moderna, Inc.BIIB Biogen Inc.
Put two of them side by side in Compare.
In FundSpec: the fair value estimate, the momentum reading, relative valuation against sector and industry peers, unusual options activity and AI model signals for RVMD are available to subscribers, with the same screen in the iOS and Android apps.
Open RVMD in FundSpec